Directorio

On the day of surgery, before the child is given anesthesia, the doctor will use a device called the Novoscope to look at the eardrum. The doctor will gently blow small puffs of air into the ear to check how the eardrum moves. This only takes about one or two minutes for each ear. During the surgery, before the ear tube is placed, the doctor will collect a small sample of fluid from the middle ear. This sample will not have the child’s name on it and will be sent to a lab for testing.

This study will happen during a child’s visit to the emergency room. There will be no extra visits after this. A doctor will first check the ears like normal and share their opinion. Then the doctor will use the Novoscope. The tip of the Novoscope will go into the outer ear, just like a regular ear check. The eardrum will get a soft puff of air, and the doctor will record an ultrasound reading. Collecting readings takes only 1 to 2 minutes for each ear. The whole study will take about 20 to 30 minutes. The study is very safe. The risks are no greater than a regular ear exam.

We are doing this study to improve treatment options for people with opioid use disorder. We want to know if a certain brain signal can better predict how someone will respond to buprenorphine (Suboxone®), and we also want to find out if a non-invasive treatment called repetitive Transcranial Magnetic Stimulation (rTMS) can help people quit opioids more easily than just taking buprenorphine alone. rTMS involves placing a coil against the scalp, and delivers magnetic pulses that stimulate a specific part of the brain. For this study, we will focus on the part of the brain involved with self-control. This procedure is FDA-approved for depression and is commonly used in other addiction treatments (smoking cessation).

We are doing this study to learn more about why some people develop pain syndromes after a stroke. We want to find out if certain brain areas, like the ventral posterior lateral nucleus of the thalamus and its connections, are linked to this pain.

We are doing this study to find the most effective, safe dose of an experimental drug called pocenbrodib (the study drug). We want to see how it works when it is given by itself and also when it is given with other drugs already approved for the treatment in people with metastatic castration-resistant prostate cancer (mCRPC).

We are doing this study to test a program that is being developed by nurses to help patients with HER2+ metastatic breast cancer manage their treatment with three drugs typically used for this diagnosis: tucatinib, trastuzumab, and capecitabine. The program's goal is to help patients manage symptoms and provide resources to improve their quality of life.

1. Complete 1 short online survey [questionnaire] (5 minutes) 2. Complete 1 interview (about 1 hour)